KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)R&D In ProcessShares IssuedShares Repurchased
Ratios

Regeneron Pharmaceuticals (REGN) Long-Term Debt Repayments: 2009-2017

Historic Long-Term Debt Repayments for Regeneron Pharmaceuticals (REGN) over the last 7 years, with Dec 2017 value amounting to -$37.1 million.

  • Regeneron Pharmaceuticals' Long-Term Debt Repayments fell 284.12% to -$37.1 million in Q4 2017 from the same period last year, while for Dec 2017 it was $51.0 million, marking a year-over-year decrease of 4.38%. This contributed to the annual value of $19.9 million for FY2017, which is 39.33% down from last year.
  • Per Regeneron Pharmaceuticals' latest filing, its Long-Term Debt Repayments stood at -$37.1 million for Q4 2017, which was down 165.09% from $57.0 million recorded in Q1 2017.
  • In the past 5 years, Regeneron Pharmaceuticals' Long-Term Debt Repayments registered a high of $159.5 million during Q4 2014, and its lowest value of -$37.1 million during Q4 2017.
  • Its 3-year average for Long-Term Debt Repayments is $24.4 million, with a median of $16.7 million in 2015.
  • In the last 5 years, Regeneron Pharmaceuticals' Long-Term Debt Repayments tumbled by 706.15% in 2013 and then skyrocketed by 17,539.94% in 2014.
  • Regeneron Pharmaceuticals' Long-Term Debt Repayments (Quarterly) stood at -$3.6 million in 2013, then soared by 4,471.44% to $159.5 million in 2014, then slumped by 87.15% to $20.5 million in 2015, then fell by 1.67% to $20.1 million in 2016, then tumbled by 284.12% to -$37.1 million in 2017.
  • Its Long-Term Debt Repayments was -$37.1 million in Q4 2017, compared to $57.0 million in Q1 2017 and $20.1 million in Q4 2016.